Aduro Biotech Inc. (NASDAQ:ADRO) received a $30.00 price objective from research analysts at Canaccord Genuity in a research note issued on Monday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price would suggest a potential upside of 115.05% from the stock’s previous close.

A number of other brokerages have also issued reports on ADRO. FBR & Co reiterated an “outperform” rating and set a $20.00 target price on shares of Aduro Biotech in a research report on Monday, November 14th. Leerink Swann set a $14.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Monday, October 24th. Finally, Roth Capital reiterated a “buy” rating and set a $20.00 target price (down from $22.00) on shares of Aduro Biotech in a research report on Thursday, October 27th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $21.33.

Analyst Recommendations for Aduro Biotech (NASDAQ:ADRO)

Aduro Biotech (NASDAQ:ADRO) traded up 0.72% on Monday, reaching $14.05. 103,442 shares of the company’s stock traded hands. Aduro Biotech has a 52-week low of $7.26 and a 52-week high of $34.95. The firm’s market capitalization is $943.91 million. The firm’s 50 day moving average price is $12.44 and its 200 day moving average price is $12.87.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by $0.09. The firm had revenue of $3.79 million for the quarter, compared to the consensus estimate of $3.99 million. Aduro Biotech had a negative return on equity of 23.45% and a negative net margin of 72.04%. Aduro Biotech’s quarterly revenue was down 79.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.01 earnings per share. On average, analysts predict that Aduro Biotech will post ($1.34) EPS for the current fiscal year.

In other Aduro Biotech news, insider Jennifer Lew sold 6,360 shares of the firm’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $14.95, for a total value of $95,082.00. Following the transaction, the insider now directly owns 48,955 shares of the company’s stock, valued at approximately $731,877.25. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Stephen T. Isaacs sold 27,273 shares of the firm’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $12.67, for a total transaction of $345,548.91. Following the completion of the transaction, the chief executive officer now directly owns 129,473 shares in the company, valued at $1,640,422.91. The disclosure for this sale can be found here. 6.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Aduro Biotech by 15.3% in the second quarter. Vanguard Group Inc. now owns 1,794,838 shares of the company’s stock valued at $20,300,000 after buying an additional 237,924 shares in the last quarter. BlackRock Fund Advisors raised its position in Aduro Biotech by 5.2% in the third quarter. BlackRock Fund Advisors now owns 1,752,256 shares of the company’s stock valued at $21,781,000 after buying an additional 87,069 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Aduro Biotech by 21.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 621,844 shares of the company’s stock valued at $7,730,000 after buying an additional 110,060 shares in the last quarter. State Street Corp raised its position in Aduro Biotech by 237.9% in the second quarter. State Street Corp now owns 543,514 shares of the company’s stock valued at $6,147,000 after buying an additional 382,654 shares in the last quarter. Finally, BVF Inc. IL purchased a new position in Aduro Biotech during the second quarter valued at approximately $5,809,000. 28.50% of the stock is currently owned by hedge funds and other institutional investors.

Aduro Biotech Company Profile

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

5 Day Chart for NASDAQ:ADRO

Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.